Clinical Trials

    Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR BCMA T Cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

    Investigator: Siddhartha Ganguly

    Study Coordinator: Pauline Ngban

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT03915184

    Phone: 346.260.9908

    Protocol Number: PRO00033043

    Description


    A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.